Corporate Update – Getinge AB (GETI‑B.ST)
Stock Performance Snapshot
- 24‑hour price action: up 2 % to SEK 268.00 (11:18 AM CET, Thursday 22 Oct 2026)
- Trading volume: SEK 269.7 million; 272.9 million shares outstanding
- Market cap: SEK 72.1 billion
- Year‑high/low: 52‑week high SEK 267.2 (21 Oct 2026); 52‑week low SEK 175.9 (23 Mar 2026)
- Moving average: 200‑day SMA at SEK 213.16
- Month‑to‑date change: +7.9 % since last month‑end
Third‑Quarter Highlights
Getinge AB reported a robust third‑quarter, exceeding market expectations on several key metrics:
| Metric | Q3 2026 | Q3 2025 | Commentary |
|---|---|---|---|
| Adjusted EBITA margin | 18.2 % | 16.4 % | Margin expansion driven by tariff refunds and favorable foreign‑exchange movements |
| Order intake | SEK 3.1 bn | SEK 2.9 bn | 7 % increase, reflecting sustained demand for acute‑care and surgical solutions |
| Net sales | SEK 5.3 bn | SEK 5.0 bn | 5 % YoY growth, modest but solid against a backdrop of global supply‑chain constraints |
| 2026 outlook | 3–5 % organic net‑sales growth | 2–4 % | Management maintains growth targets, emphasizing the need for continued order flow to hit full‑year goals |
Key takeaways for investors:
- Margin resilience – Tariff refunds and currency hedging have cushioned profitability, positioning Getinge to deliver a higher operating margin than forecasted.
- Order pipeline – The company’s order intake trajectory suggests that the upcoming 12‑month cash‑flow profile will remain strong, supporting the 2026 sales outlook.
- Product momentum – The launch of Cardiohelp II in the Acute Care Therapies segment is expected to capture a growing share of the market for cardiac support devices, potentially driving incremental revenue.
Market Sentiment
The Stockholm market has reacted positively:
- The share price has reached a 52‑week high, reinforcing bullish sentiment among institutional and retail investors.
- Analysts across the board maintain buy recommendations with a price target of SEK 270.
- The upward trend is reinforced by consistent performance across Getinge’s three business segments, each contributing to a diversified revenue stream.
Comparative Context
In the past 24 hours, other Swedish equities have mirrored the market’s upward drift:
| Stock | % Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| Octave Intelligence (OCTV) | +3.27 % | USD 21.16 | USD 5.5 bn | – |
| Castellum (CAST.ST) | +0.88 % | SEK 132.8 | SEK 54.4 bn | 22.91 |
| Avanza Bank (AZA.ST) | +1.55 % | SEK 355.7 | SEK 57 bn | 19.58 |
| Sectra‑B (SECT-B.ST) | +2.48 % | SEK 335.6 | SEK 63.1 bn | 101.95 |
| Beijer Ref (BEIJ-B.ST) | +1.16 % | SEK 155 | SEK 75.1 bn | 31.52 |
The broader Swedish equity market’s upward momentum suggests a favorable environment for value‑driven, high‑quality firms like Getinge.
Forward‑Looking Outlook
- Strategic execution – Getinge’s management remains focused on expanding the Acute Care Therapies portfolio while deepening penetration in Surgical Workflows and Life Science.
- Capital allocation – The firm’s strong cash‑flow profile affords flexibility to invest in R&D, strategic acquisitions, and potential share‑repurchase programs.
- Risk management – Continued vigilance over currency exposure, supply‑chain robustness, and regulatory developments will be essential to sustain momentum.
In sum, Getinge AB is poised to capitalize on its operational strengths and market positioning, offering investors a compelling blend of profitability, growth potential, and disciplined capital management.
